Arthritis Rx for Immuno Disorders: 64.5% of denials overturned
In 141 California IMR decisions from 2002 to 2026, reviewers overturned 91 (64.5%). In the last five years: 75.4% of 57. 128 were medical-necessity disputes, 13 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 19 | 78.9% |
| 2022 | 16 | 75.0% |
| 2023 | 8 | 50.0% |
| 2024 | 5 | 80.0% |
| 2025 | 8 | 87.5% |
| 2026 | 1 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 45 | 62.2% | 64.5% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 39 | 79.5% | 64.5% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 39 | 61.5% | 64.5% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 30 | 3.3% | 64.5% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 26 | 42.3% | 64.5% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 8 | 50.0% | 64.5% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 6 | 100.0% | 64.5% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Otezla. Otezla (apremilast) is indicated for patients with active psoriatic arthritis. Treatment guidelines recognize apremilast as an appropriate systemic therapy, particularly in patients with mild to moderate peripheral disease. Current expert consensus supports its use in patients with moderately active, non-erosive psoriatic …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Simponi Aria infusions, 2 mg/kg at week zero and week four, then every eight weeks for one year.The records document that this patient has a history of active rheumatoid arthritis despite prior treatment. Per the American College of Rheumatology (ACR) guidelines, the …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Otezla used in combination with the approved Bimzelx. Recent leading expert recommendations for psoriatic arthritis support the concept of combination or dual advanced therapy for patients who fail multiple monotherapies and still experience high disease activity or poor quality of life. These …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary:A patient has requested authorization and coverage for Ruxience infusions at an increased frequency. The patient has a history of rheumatoid arthritis and interstitial lung disease and has been receiving treatment with rituximab in combination with other therapy. In this case, the requested dosing frequency exceeds standard approved dosing guidelines. Additionally, …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Arthritis Rx denials for Immuno Disorders overturned?
In 141 California IMR decisions from 2002 to 2026, reviewers overturned 91 (64.5%). In the last five years: 75.4% of 57. 128 were medical-necessity disputes, 13 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.